stockrow
Friday 6 November 2026
Export CTSO’s income statement to Excel — free account
Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024.
- Revenue
- +0.17%
- EPS
- −333.3%
- Free cash flow
- +64.9%
- Total debt
- +19.9%
Quarter to June 2026, against a year earlier
4.75
0.15
+3.26%
Follow CTSO
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 4 | 3 | 5 | 2 | 2 | 4 | 4 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
15.08 | 11.94 | 11.03 | 4.98 | 7.55 | 4.21 | 2.29 | 1.54 | 1.39 | 1.07 |
Altman Z-Score |
(13.26) | (1.14) | 1.59 | (7.44) | 15.27 | 0.91 | (4.81) | (7.63) | (8.26) | (9.24) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(53.66) | (19.06) | (14.10) | (24.36) | 5.12 | (3.61) | (12.62) | (19.25) | (21.30) | (23.50) |
P/Operating CF |
(133.17) | (441.69) | (91.69) | (30.11) | (292.47) | (33.08) | (14.85) | (7.46) | (21.16) | (8.24) |
Beneish M-Score |
(4.37) | (2.38) | (2.51) | (2.95) | (2.27) | (2.48) | (2.08) | (3.30) | (3.06) | (2.11) |
P/B ratio |
107.44 | 17.62 | 14.66 | 36.33 | 3.91 | 2.90 | 2.24 | 2.03 | 4.46 | 6.74 |
Price to Tangible BV |
107.44 | 17.62 | 14.66 | 2,190.22 | 4.13 | 3.14 | 2.56 | 2.50 | 6.71 | 14.85 |
EV/Sales |
15.05 | 11.45 | 10.48 | 5.09 | 5.83 | 3.32 | 1.80 | 1.24 | 1.62 | 1.42 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(21.30) | (26.86) | (21.75) | (7.58) | (42.58) | (10.24) | (2.21) | (1.79) | (4.00) | (4.26) |
EV/FCF |
(19.57) | (21.32) | (19.08) | (6.95) | (32.79) | (7.84) | (1.79) | (1.71) | (3.83) | (4.12) |
Quick Ratio |
1.56 | 2.49 | 3.80 | 1.68 | 7.54 | 4.14 | 2.86 | 1.44 | 1.59 | 1.42 |
Current Ratio |
1.83 | 2.64 | 4.09 | 2.10 | 8.12 | 4.70 | 3.48 | 1.81 | 2.20 | 2.13 |
Net Debt/EBITDA |
0.03 | 0.77 | 0.82 | (0.15) | 7.50 | 1.77 | 0.56 | 0.30 | (0.40) | (0.85) |
Debt/Assets |
50.67% | 41.46% | 29.07% | 54.97% | 1.14% | 15.44% | 8.08% | 9.52% | 29.54% | 37.72% |
Debt/Equity |
3.67 | 0.97 | 0.59 | 4.40 | 0.01 | 0.22 | 0.14 | 0.21 | 1.26 | 2.82 |
Asset Turnover |
0.91 | 0.90 | 0.77 | 0.81 | 0.70 | 0.48 | 0.45 | 0.54 | 0.71 | 0.81 |
Operating CF/Net income |
0.57 | 0.73 | 0.63 | 0.87 | 0.72 | 0.57 | 0.86 | 0.74 | 0.70 | 1.51 |
Capex/Depreciation |
(3.10) | (5.59) | (3.12) | (2.18) | (1.70) | (3.79) | (5.70) | (0.46) | (0.31) | (0.17) |
Interest Coverage |
— | — | — | — | — | (812.31) | (237.72) | — | (11.76) | (5.65) |
| (246.41%) | (151.66%) | (126.57%) | (189.32%) | (18.97%) | (34.64%) | (67.00%) | (99.38%) | (119.80%) | (96.39%) | |
| (112.31%) | (52.05%) | (59.04%) | (62.57%) | (13.36%) | (27.37%) | (42.96%) | (50.34%) | (41.30%) | (17.91%) | |
ROIC |
(715.47%) | (209.74%) | (216.12%) | (190.11%) | (73.46%) | (58.59%) | (107.43%) | (138.73%) | (61.12%) | (56.48%) |
Return on Tangible Assets |
(285.54%) | (61.54%) | (74.58%) | (149.46%) | (10.53%) | (44.04%) | (94.32%) | (136.54%) | (99.70%) | (43.73%) |
Average Days of Receivables |
54.92 | 53.14 | 63.95 | 65.35 | 45.93 | 38.25 | 59.61 | 71.12 | 75.06 | 74.35 |
Research and Development Expense of Revenue |
42.75% | 21.26% | 34.32% | 48.47% | 21.49% | 37.95% | 43.58% | 50.17% | 21.37% | 13.72% |
Selling, General and Administrative Expense of Revenue |
123.94% | 98.44% | 92.76% | 88.20% | 69.42% | 82.82% | 98.84% | 123.23% | 94.77% | 96.17% |
Intangible Assets out of Total Assets |
0.12 | 0.08 | 0.08 | 0.12 | 0.05 | 0.05 | 0.07 | 0.00 | 0.08 | 0.07 |
Share Based Compensation of Revenue |
33.46% | 26.43% | 23.93% | 11.38% | 11.48% | 14.37% | 10.95% | 13.37% | 10.56% | 7.46% |
Graham Net Nets |
0.00 | 0.04 | 0.04 | (0.02) | 0.23 | 0.21 | 0.07 | (0.09) | (0.30) | (0.44) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(7.89%) | (4.61%) | (6.93%) | (15.58%) | (2.51%) | (13.60%) | (41.61%) | (61.79%) | (42.97%) | (21.05%) |
Free Cash Flow Yield |
(5.10%) | (4.50%) | (4.98%) | (14.72%) | (2.36%) | (10.07%) | (43.74%) | (47.28%) | (30.48%) | (32.17%) |
Revenue per Share |
7.49 | 10.97 | 14.65 | 15.47 | 21.13 | 19.91 | 15.92 | 13.92 | 13.08 | 11.91 |
Operating CF per Share |
(5.29) | (4.68) | (7.06) | (10.39) | (2.89) | (6.46) | (12.96) | (9.70) | (5.30) | (3.98) |
Capex per Share |
(0.47) | (1.22) | (0.99) | (0.94) | (0.86) | (1.97) | (2.96) | (0.42) | (0.25) | (0.13) |
Free Cash Flow per Share |
(5.76) | (5.89) | (8.05) | (11.33) | (3.76) | (8.43) | (15.92) | (10.12) | (5.55) | (4.11) |
Cash per Share |
4.12 | 12.55 | 14.56 | 7.58 | 36.80 | 24.05 | 10.16 | 6.33 | 3.04 | 2.01 |
Shareholders Equity per Share |
1.05 | 7.43 | 11.03 | 2.12 | 40.81 | 28.86 | 16.24 | 10.52 | 4.08 | 1.90 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.05 | 7.43 | 11.03 | 2.12 | 40.81 | 28.86 | 16.24 | 10.52 | 4.08 | 1.90 |
Free Cash Flow |
(7.33) | (8.14) | (12.36) | (18.28) | (7.29) | (18.29) | (34.69) | (22.59) | (15.10) | (12.79) |
Working Capital |
3.55 | 12.89 | 21.35 | 10.97 | 72.30 | 50.61 | 24.05 | 11.36 | 11.78 | 10.93 |
Capital Expenditures |
(0.60) | (1.68) | (1.52) | (1.52) | (1.68) | (4.28) | (6.46) | (0.94) | (0.67) | (0.41) |
Net Current Asset Value |
(0.53) | 6.90 | 11.00 | (3.06) | 71.72 | 37.36 | 5.90 | (4.08) | (14.66) | (17.64) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.11 | 0.07 | 0.06 | 0.04 | 0.10 | 0.19 | 0.03 | 0.02 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.21 | 0.28 | 0.36 | 0.46 | 0.22 | 0.11 | 0.20 | 0.24 | 0.31 |
Cash ROIC |
(63.74%) | (21.66%) | (25.10%) | (59.54%) | (4.81%) | (14.23%) | (55.39%) | (52.96%) | (45.22%) | (44.39%) |
Accounts Receivable Turnover |
9.15 | 8.33 | 7.32 | 5.93 | 8.52 | 8.92 | 6.81 | 5.30 | 5.32 | 4.98 |
Accounts Payable Turnover |
3.92 | 4.29 | 5.49 | 4.18 | 5.71 | 4.76 | 6.26 | 3.35 | 3.00 | 3.41 |
Inventory Turnover |
3.91 | 6.77 | 9.20 | 5.00 | 4.62 | 2.97 | 3.39 | 2.67 | 3.51 | 2.64 |
Average Days of Payables |
122.79 | 82.31 | 72.41 | 101.08 | 60.60 | 92.68 | 43.29 | 151.98 | 113.85 | 99.05 |
Days of Inventory on Hand |
76.99 | 52.63 | 40.60 | 104.78 | 88.30 | 157.47 | 90.53 | 134.93 | 93.16 | 182.33 |
Average Receivables |
1.04 | 1.82 | 3.07 | 4.21 | 4.81 | 4.84 | 5.09 | 5.86 | 6.69 | 7.44 |
Average Payables |
1.01 | 1.29 | 1.37 | 1.76 | 1.94 | 2.32 | 2.23 | 2.73 | 3.57 | 3.10 |
Average Inventory |
1.01 | 0.81 | 0.81 | 1.47 | 2.39 | 3.72 | 4.11 | 3.42 | 3.05 | 4.01 |
Average Assets |
10.47 | 16.90 | 29.15 | 30.79 | 58.67 | 89.73 | 76.38 | 58.09 | 50.16 | 45.78 |
Average Common Equity |
4.77 | 5.80 | 13.60 | 10.18 | 41.32 | 70.90 | 48.98 | 29.43 | 17.29 | 8.51 |
Columns are period end dates · fundamentals updated 26 Oct 2026